Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

GenScience Acquires Rights to Prostate Cancer Therapy in $132 Million Agreement

publication date: Nov 17, 2020

GenScience Pharma acquired China rights to two long-acting depot delivery devices for prostate cancer from Foresee Pharma of Taiwan in a $132 million agreement. The ready-to-use subcutaneous 6-month and 3-month depot formulations, Camcevi™, which will deliver leuprolide mesylate, are currently under review for approval in the US and EU. GenSci will pay $8 million upfront and up to $124 million n milestones, plus royalties. GenSci is a wholly owned subsidiary of Changchun High-Tech Industry. More details....

Stock Symbols: (TWO: 6576) (SHZ: 000661)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.